- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03796559
Magseed aktivert langsiktig lokalisering av aksillære lymfeknuter (MAGELLAN)
En prospektiv åpen undersøkelse av bruken av Magseed®-markører og Sentimag® for å lokalisere aksillære lymfeknuter med biopsi-påviste metastaser hos brystkreftpasienter
The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a post-market, prospective, open-label, single arm study of Magseed and Sentimag in patients with breast cancer with biopsy-proven axillary node metastases who had a clip placed to mark the metastatic node and are having that clipped node selectively removed at surgery following neo-adjuvant chemotherapy (NAC). Subjects will have the Magseed placed to mark axillary lymph nodes with biopsy-proven metastasis under ultrasound guidance before initiating NAC. After completion of NAC, the Magseed will be localized using the Sentimag system during surgery and removed with the targeted lymph node.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Matt Womack, PhD
- Telefonnummer: +447851247439
- E-post: mwomack@endomag.com
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
Underetterforsker:
- Kelly Hunt, MD, F.A.C.S.
-
Ta kontakt med:
- Veronika Noregil
- E-post: VYNovegil@mdanderson.org
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Baylor Medicine
-
Ta kontakt med:
- Ivan Marin
- E-post: ivan.marin@bcm.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18 years or older at time of consent
- Histologically confirmed cT0-4, N1 breast cancer
- Axillary lymph node metastasis with pathologic confirmation by needle biopsy
- Clip placed in the sampled axillary lymph node before initiation of chemotherapy
- Planned for neo-adjuvant chemotherapy prior to surgical resection
- Eligible for targeted axillary dissection (defined as selective localization and removal of the clipped node and SLND) at the completion of neo-adjuvant chemotherapy
- ECOG performance status 0-2
Exclusion Criteria:
- Distant metastases
- Inflammatory breast cancer
- Prior ipsilateral axillary surgical procedure including SLND or axillary node excision
- Prior history of breast cancer in the ipsilateral breast
- History of lymphoma
- Subject is pregnant
- Previous radiation to the breast or axilla
- Pacemaker or other implantable cardiac device in the ipsilateral chest wall
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Magseed marker
Magseed marker deployed percutaneously, prior to patient undergoing neo-adjuvant chemotherapy (NAC), under ultrasound guidance to mark a lymph node intended for selective surgical removal post NAC. |
Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Retrieval rate of clipped node and Magseed in the excised specimen
Tidsramme: Time of surgery
|
The retrieval rate of the clipped node and Magseed in the excised specimen. This is defined as the number of subjects in whom the clipped node and Magseed are retrieved in a single excised specimen divided by the total number of subjects. |
Time of surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rates of device and serious device-related events
Tidsramme: Up to 42 days post-surgery
|
Rates of device-related adverse events and serious device-related adverse events |
Up to 42 days post-surgery
|
|
Radiologic rated ease of Magseed placement
Tidsramme: Time of Magseed marker placement
|
5 point Likert scale, very easy = 5, very difficult = 1 |
Time of Magseed marker placement
|
|
Radiologic placement accuracy
Tidsramme: Between completion of NAC time of surgery
|
Success rate of seed placement (placement accuracy) |
Between completion of NAC time of surgery
|
|
Radiologic seed position
Tidsramme: After completion of NAC
|
Success rate of maintained seed position at the completion of NAC |
After completion of NAC
|
|
Surgical nodes localized
Tidsramme: Time of surgery
|
Number of nodes retrieved within the surgical specimen containing the Magseed |
Time of surgery
|
|
Ease of surgical localization
Tidsramme: Time of surgery
|
5 point Likert scalevery easy = 5, very difficult = 1 |
Time of surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Abigail Caudle, MD, MS, MD Anderson Cancer Center, Houston, TX
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- US-003
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .